BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 21254947)

  • 1. Pharmacotherapy for squamous-cell carcinoma of the head and neck.
    Papaspyrou G; Werner JA; Dietz A
    Expert Opin Pharmacother; 2011 Feb; 12(3):397-409. PubMed ID: 21254947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapeutic target for head and neck squamous cell carcinoma: HGF-MET signaling pathway.
    Lau PC; Chan AT
    Anticancer Drugs; 2011 Aug; 22(7):665-73. PubMed ID: 21709616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel targeted therapies in head and neck cancer.
    Ferreira MB; Lima JP; Cohen EE
    Expert Opin Investig Drugs; 2012 Mar; 21(3):281-95. PubMed ID: 22239178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galanin receptor subtypes 1 and 2 as therapeutic targets in head and neck squamous cell carcinoma.
    Kanazawa T; Misawa K; Carey TE
    Expert Opin Ther Targets; 2010 Mar; 14(3):289-302. PubMed ID: 20148716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standard, and novel cytotoxic and molecular-targeted, therapies for HNSCC: an evidence-based review.
    Murdoch D
    Curr Opin Oncol; 2007 May; 19(3):216-21. PubMed ID: 17414639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging molecular targeted therapies in the treatment of head and neck cancer.
    Bozec A; Peyrade F; Fischel JL; Milano G
    Expert Opin Emerg Drugs; 2009 Jun; 14(2):299-310. PubMed ID: 19519286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.
    Sundvall M; Karrila A; Nordberg J; Grénman R; Elenius K
    Expert Opin Emerg Drugs; 2010 Jun; 15(2):185-201. PubMed ID: 20415599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
    Le Tourneau C; Siu LL
    Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel associated pathways in cisplatin resistant head and neck squamous cell carcinoma: a pilot study.
    Yoo GH; Lin HS; Iskander AJ; Piechocki MP; Oliver J; Kewson D; Lonardo F; Tainsky MA; Kim HR; Kim H; Ensley JF
    Laryngoscope; 2005 Nov; 115(11):1938-46. PubMed ID: 16319602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor biology in head and neck cancer.
    Kalyankrishna S; Grandis JR
    J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 as a therapeutic target in head and neck squamous cell carcinoma.
    Pollock NI; Grandis JR
    Clin Cancer Res; 2015 Feb; 21(3):526-33. PubMed ID: 25424855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC).
    Azoury SC; Gilmore RC; Shukla V
    Discov Med; 2016 Jun; 21(118):507-16. PubMed ID: 27448787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck.
    Gilbert J; Argiris A
    Clin Adv Hematol Oncol; 2006 Aug; 4(8):611-9. PubMed ID: 17099619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer.
    Rodriguez-Pinilla M; Rodriguez-Peralto JL; Hitt R; Sanchez JJ; Ballestin C; Diez A; Sanchez-Verde L; Alameda F; Sanchez-Cespedes M
    Clin Cancer Res; 2004 Dec; 10(24):8486-92. PubMed ID: 15623629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy of head and neck squamous cell carcinoma.
    Pan Q; Gorin MA; Teknos TN
    Expert Opin Pharmacother; 2009 Oct; 10(14):2291-302. PubMed ID: 19663637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
    Corvò R
    Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
    Schultz JD; Mühlheim K; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
    Oncol Rep; 2011 Nov; 26(5):1099-109. PubMed ID: 21805039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
    Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
    Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy in the management of advanced cutaneous squamous cell carcinoma in organ transplant recipients: theoretical and practical considerations.
    Martinez JC; Otley CC; Okuno SH; Foote RL; Kasperbauer JL
    Dermatol Surg; 2004 Apr; 30(4 Pt 2):679-86. PubMed ID: 15061855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of resistance to EGFR inhibitors in head and neck cancer.
    Cooper JB; Cohen EE
    Head Neck; 2009 Aug; 31(8):1086-94. PubMed ID: 19378324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.